|Product Candidate / PROGRAM||Drug substance||Indication||Discovery||Pre-clinical||Phase 1||Phase 2||Phase 3/ Pivotal||EMA/FDA review||Commercial Rights|
|ERYZYME||Therapeutic enzymes||Metabolic diseases|
ERYZYME covers the application of our ERYCAPS platform to enzyme-based therapies beyond oncology. As with our lead program eryaspase, we encapsulate therapeutic enzymes in red blood cells to deliver superior outcomes through long-acting efficacy and reduced adverse reaction vs. non-encapsulated enzymes.
Under the ERYZYME approach, Erytech is currently advancing a pipeline of novel and highly differentiated programs for rare and highly specialized conditions.